BOULDER, Colo., April 23, 2014 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the third quarter of fiscal 2014 and hold a conference call to discuss those results on Tuesday, April 29, 2014. Ron Squarer, Chief Executive Officer and Michael Carruthers, Chief Financial Officer will lead the call.
Conference Call Information
Tuesday, April 29, 2014
9:00 a.m. eastern time
Webcast, including Replay and Conference Call Slides:
About Array BioPharma Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Seven Phase 3 or pivotal studies are already in progress, or are planned to begin, within the next year. These programs include the wholly-owned hematology drug, filanesib for multiple myeloma and two partnered cancer drugs, selumetinib (AstraZeneca) and binimetinib (Novartis). For more information on Array, please go to www.arraybiopharma.com